COVID-19 Clinical Trial
Official title:
LIFE STYLE BEFORE COVID 19 INFECTION IMPACT ON THE PROGRESS OF COVID 19
Verified date | January 2022 |
Source | Fatih Sultan Mehmet Training and Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
THE EFFECT OF LIFESTYLE ON THE PROGRESS OF COVID 19 INFECTION The development of COVID 19 disease depends on the interaction with the immunity of the host. The immune response of the host is related to age, gender, nutrition, sleep and physical activity. Our study in Fatih Sultan Mehmet Training and Research Hospital; Between 31 January-31 May 2021,positive COVID 19 PCR test was performed with 66 patients over the age of 50, who received inpatient treatment. Demographic data of the patients, length of hospitalization, alcohol/tobacco use, BMI, comorbidities, regular use medication or not, thorax CT findings, place of discharge after treatment, laboratory parameters were recorded at hospitalization and discharge. To evaluate the pre-infection lifestyle; physical activity, nutrition and sleep habits were questioned. According to the PSQS (Pittsburg Sleep Quality Scale) although the increase in discharged lymphocyte measurements compared to the first hospitalization of the patients in the good and bad sleep groups was significant, there was no significant difference between the groups. In the evaluation between the groups, the increase in the NLR value at the first hospitalization was significant in the bad sleep group compared to the good sleep group. There was no difference between the groups in terms of NLR. According to the MNA(Mini Nutritional Assessment)scale ;the increase in the discharge lymphocyte value of the groups compared to the value at the first hospitalization was significant. The increases in the discharge lymphocyte measurements of the patients compared to the first hospitalization were significant between the groups (p<0.05). The increase in discharge lymphocyte values in patients at risk of malnutrition compared to the first hospitalization was higher than in patients with malnutrition (p<0.05). The decrease in discharge NLR values compared to the first hospitalization was significant in the group under normal nutrition and malnutrition risk. The difference between the first hospitalization PLT (Platelet)measurements of the groups according to the MNA scale was significant. According to the International Brief Physical Activity Survey; the increase in the discharge lymphocyte value of the inactive, minimally active and very active groups was significant compared to the first hospitalization. A significant difference was found between the PLT measurements between the groups (p<0.05). PLT measurements of very active cases were higher than those of minimally active cases (p<0.05). In this study, in which we examined the effects of lifestyle before the diagnosis of COVID 19 on the course of COVID 19, we observed that there is no need for intensive care in patients who are well fed, have good sleep quality and are physically active.
Status | Active, not recruiting |
Enrollment | 66 |
Est. completion date | February 1, 2022 |
Est. primary completion date | November 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: COVID 19 pcr test positive over 50 years of age, inpatient treatment patients with pandemic service received ethics committee approval Exclusion Criteria: COVID 19 pcr negative Under 50 years of age, Lymphatic system patients with disease or malignant hematological diseases |
Country | Name | City | State |
---|---|---|---|
Turkey | Yildiz | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Fatih Sultan Mehmet Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pittsburgh Sleep Quality Index (PSQI) . | SLEEP QUALITY SCALE The total PSQI score is obtained by summing the seven sub-scores. The total score ranges from 9 to 21. The PSQI total score clearly distinguishes good sleepers from bad sleepers.
Good sleep:5 points or less Bad Sleep:over 5 points |
UP TO 24 WEEKS | |
Primary | Mini Nutritional Assessment | NUTRITIONAL STATUS
The sum of the MNA score distinguishes between elderly patients with: Adequate nutritional status, MNA 24; Protein-calorie malnutrition, MNA 17; at risk of malnutrition, MNA between 17 and 23.5. Normal nutritional status:24-30 points At risk of malnutrition:17-23.5 Malnourished:under 17 points |
UP TO 24 WEEKS | |
Primary | International Short Physical Activiiy Questionnaire | Category 1:INACTIVE
It is the lowest level of physical activity. Conditions that cannot be included in categories 2 and 3 are considered inactive. Category 2:MINIMUM ACTIVE 2 a:Doing vigorous activity for at least 20 minutes on 3 or more days 2b:5 or more days of moderate-intensity activity or walking for at least 30 minutes a day 2c:A combination of 5 or more days of walking and moderate-intensity activity providing a minimum of 600 MET-min/week Category 3:VERY ACTIVE 3 a:At least 3 days of vigorous physical activity or more days providing a minimum of 1500 MET-min/week 3b:Moderate to vigorous walking for 7 days providing a minimum of 3000 MET-min/week combination of activity |
UP TO 24 WEEKS | |
Secondary | LYMPHOCYTE COUNT | HEMATOLOGICAL BIOMARKER | UP TO 24 WEEKS | |
Secondary | NEUTROPHIL LYMPHOCYTE RATIO | HEMATOLOGICAL BIOMARKER | UP TO 24 WEEKS | |
Secondary | PLATELET COUNT | HEMATOLOGICAL BIOMARKER | UP TO 24 WEEKS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|